CN116669763A - Fgfr抑制剂联合疗法 - Google Patents

Fgfr抑制剂联合疗法 Download PDF

Info

Publication number
CN116669763A
CN116669763A CN202180076145.8A CN202180076145A CN116669763A CN 116669763 A CN116669763 A CN 116669763A CN 202180076145 A CN202180076145 A CN 202180076145A CN 116669763 A CN116669763 A CN 116669763A
Authority
CN
China
Prior art keywords
genetic alteration
inhibitor
patient
fgfr3
egfr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180076145.8A
Other languages
English (en)
Chinese (zh)
Inventor
A·E·圣地亚哥-沃克尔
C·H·莫伊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Pharmaceutica NV
Original Assignee
Janssen Pharmaceutica NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica NV filed Critical Janssen Pharmaceutica NV
Publication of CN116669763A publication Critical patent/CN116669763A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Analytical Chemistry (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CN202180076145.8A 2020-09-14 2021-09-13 Fgfr抑制剂联合疗法 Pending CN116669763A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063078193P 2020-09-14 2020-09-14
US63/078193 2020-09-14
PCT/EP2021/075145 WO2022053697A1 (en) 2020-09-14 2021-09-13 Fgfr inhibitor combination therapies

Publications (1)

Publication Number Publication Date
CN116669763A true CN116669763A (zh) 2023-08-29

Family

ID=77821784

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180076145.8A Pending CN116669763A (zh) 2020-09-14 2021-09-13 Fgfr抑制剂联合疗法

Country Status (10)

Country Link
US (1) US20230321087A1 (https=)
EP (1) EP4210702A1 (https=)
JP (1) JP2023542296A (https=)
KR (1) KR20230069958A (https=)
CN (1) CN116669763A (https=)
AU (1) AU2021339962A1 (https=)
CA (1) CA3191538A1 (https=)
MX (1) MX2023002980A (https=)
TW (1) TW202228695A (https=)
WO (1) WO2022053697A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202308689A (zh) * 2021-04-21 2023-03-01 美商健生生物科技公司 高濃度的雙特異性抗體調配物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107660205A (zh) * 2015-04-03 2018-02-02 因赛特公司 作为lsd1抑制剂的杂环化合物
US20180362654A1 (en) * 2015-12-11 2018-12-20 Regeneron Pharmaceuticals, Inc. Methods for Reducing or Preventing Growth of Tumors Resistant to EGFR and/or ErbB3 Blockade
CN110869392A (zh) * 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
WO2020131627A1 (en) * 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN111420060A (zh) * 2020-03-30 2020-07-17 南方医科大学南方医院 一种抗肿瘤的联合用药组合物及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
EP0281604B1 (en) 1986-09-02 1993-03-31 Enzon Labs Inc. Single polypeptide chain binding molecules
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
AUPO591797A0 (en) 1997-03-27 1997-04-24 Commonwealth Scientific And Industrial Research Organisation High avidity polyvalent and polyspecific reagents
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
WO2005110076A2 (en) 2004-05-10 2005-11-24 Children's Medical Center Corporation Braf expression in zebrafish and uses thereof
EP3042964A1 (en) 2004-06-04 2016-07-13 Genentech, Inc. Egfr mutations
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
BRPI0611375A2 (pt) 2005-05-23 2010-08-31 Novartis Ag formas cristalinas e outras de sais de ácido láctico de 4-amino-5-flúor-3-[6-(4-metilpiperazin-1-il)-1h-benzimid azol-2-il]-1h-quinolin-2-ona
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
AU2008343589A1 (en) 2007-12-19 2009-07-09 Centocor Ortho Biotech Inc. Design and generation of human de novo pIX phage display libraries via fusion to pIX or pVII, vectors, antibodies and methods
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
MX361088B (es) * 2012-11-21 2018-11-26 Janssen Biotech Inc Anticuerpos del receptor del factor de crecimiento epidérmico aislado/del receptor del factor de crecimiento de hepatocitos (egfr/c-met) biespecíficos.
KR102470456B1 (ko) 2014-09-26 2022-11-23 얀센 파마슈티카 엔.브이. Fgfr 억제제를 사용한 치료에 반응할 암 환자를 확인하는 데 있어서 fgfr 돌연변이 유전자 패널의 사용
HUE054848T2 (hu) 2014-10-13 2021-09-28 Yuhan Corp Vegyületek és készítmények EGFR mutáns kináz aktivitás módosítására
CN111868260B (zh) * 2017-08-07 2025-02-21 约翰斯霍普金斯大学 用于评估和治疗癌症的方法和材料
MA55486A (fr) * 2019-03-29 2022-02-09 Janssen Pharmaceutica Nv Inhibiteurs de la tyrosine kinase fgfr pour le traitement du carcinome urothélial
WO2020208592A1 (en) * 2019-04-12 2020-10-15 Dr. Reddy’S Laboratories Limited Process for preparation of erdafitinib, its purification and amorphous solid dispersion

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107660205A (zh) * 2015-04-03 2018-02-02 因赛特公司 作为lsd1抑制剂的杂环化合物
US20180362654A1 (en) * 2015-12-11 2018-12-20 Regeneron Pharmaceuticals, Inc. Methods for Reducing or Preventing Growth of Tumors Resistant to EGFR and/or ErbB3 Blockade
CN110869392A (zh) * 2017-05-16 2020-03-06 百时美施贵宝公司 用抗gitr激动性抗体治疗癌症
WO2020131627A1 (en) * 2018-12-19 2020-06-25 Array Biopharma Inc. Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases
CN111420060A (zh) * 2020-03-30 2020-07-17 南方医科大学南方医院 一种抗肿瘤的联合用药组合物及其应用

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
HAURA ERIC B，等: "Erdafitinib Overcomes FGFR3-TACC3-Mediated Resistance to Osimertinib", JOURNAL OF THORACIC ONCOLOGY, vol. 15, no. 19, 24 August 2020 (2020-08-24), pages 154 *
MARIA TERESA HERRERA-ABREU，等: "Parallel RNA Interference Screens Identify EGFR Activation as an Escape Mechanism in FGFR3-Mutant Cancer", CANCER DISCOVER, vol. 3, no. 9, 1 September 2013 (2013-09-01), pages 1058 - 1071, XP055532713, DOI: 10.1158/2159-8290.CD-12-0569 *
MASARU KATOH ，等: "Fibroblast growth factor receptors as treatment targets in clinical oncology", NATURE REVIEWS CLINICAL ONCOLOGY, vol. 16, no. 12, 26 October 2018 (2018-10-26), pages 105 - 122, XP036705943, DOI: 10.1038/s41571-018-0115-y *
RUIZ-LLORENTE SERGIO，等: "Mechanisms of resistance to FGFR inhibitors in urothelial cancer cell lines and patients harboring FGFR3 alterations and strategies to overcome it", CANCER RESEARCH, vol. 80, no. 16, 15 August 2020 (2020-08-15), pages 1 - 2 *
SASE HITOSHI，等: "Acquired JHDM1D-BRAF Fusion Confers Resistance to FGFR Inhibition in FGFR2-Amplified Gastric Cancer", MOLECULAR CANCER THERAPEUTICS, vol. 17, no. 10, 1 October 2018 (2018-10-01), pages 2217 - 2225, XP055864622, DOI: 10.1158/1535-7163.MCT-17-1022 *
VIPIN YADAV，等: "Reactivation of Mitogen-activated Protein Kinase (MAPK) Pathway by FGF Receptor 3 (FGFR3)/Ras Mediates Resistance to Vemurafenib in Human B-RAF V600E Mutant Melanoma", J BIOL CHEM, vol. 287, no. 33, 22 June 2012 (2012-06-22), pages 28087 - 28098, XP055141868, DOI: 10.1074/jbc.M112.377218 *

Also Published As

Publication number Publication date
MX2023002980A (es) 2023-06-06
TW202228695A (zh) 2022-08-01
JP2023542296A (ja) 2023-10-06
KR20230069958A (ko) 2023-05-19
AU2021339962A1 (en) 2023-05-25
WO2022053697A1 (en) 2022-03-17
US20230321087A1 (en) 2023-10-12
CA3191538A1 (en) 2022-03-17
EP4210702A1 (en) 2023-07-19

Similar Documents

Publication Publication Date Title
US11572405B2 (en) Combination therapy with anti-IL-8 antibodies and anti-PD-1 antibodies for treating cancer
TW201819640A (zh) 癌症之治療性及診斷性方法
TW201705979A (zh) 用於具ｅｇｆｒ突變陽性之非小細胞肺癌的組合療法
CN111629729A (zh) 治疗癌症的方法及组合疗法
JP2020114849A (ja) Ｅｇｆｒ依存性疾患またはｅｇｆｒファミリーメンバーを標的とする薬剤に対して獲得耐性を有する疾患の治療における２−カルボキサミドシクロアミノウレア誘導体の使用
CN110636861A (zh) 用于治疗癌症的包含小分子csf-1r抑制剂和特异性地结合cd40的激动性抗体的协同疗法
JP2022027658A (ja) チロシンキナーゼ阻害剤と併用してｅｇｆ／ｅｇｆｒ経路を抑制する方法および組成物
TWI900527B (zh) 用於治療尿路上皮癌的ｆｇｆｒ酪胺酸激酶抑制劑和抗ｐｄ１藥劑
AU2023215753A1 (en) Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
CN116669763A (zh) Fgfr抑制剂联合疗法
CN116568326A (zh) 用于治疗实体瘤的方法及包括krasg12c抑制剂和vegf抑制剂的组合物
WO2023138576A1 (zh) 螺环芳基磷氧化物与抗egfr抗体的药物组合
CN108367003B (zh) 乳腺癌脑转移的治疗
WO2026038160A1 (en) Methods for reducing infusion-related reactions in patients treated with egfr/met bispecific antibodies
WO2023138574A1 (zh) 螺环芳基磷氧化物与抗vegf抗体的药物组合
HK40081114A (en) Fgfr tyrosine kinase inhibitors and anti-pd1 agents for the treatment of urothelial carcinoma
EP4642443A1 (en) Treatment of cancer with a combination of an antibody that binds egfr and cytotoxic drugs
HK40116078A (zh) 用於减少使用egfr/met双特异性抗体治疗的患者的输注相关反应的方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination